William J Hadden1, Philip R de Reuver2, Kai Brown3, Anubhav Mittal3, Jaswinder S Samra3, Thomas J Hugh4. 1. Northern Clinical School, University of Sydney, Sydney, New South Wales, Australia. 2. Upper GI Surgical Unit, Royal North Shore Hospital and North Shore Private Hospital, Sydney, New South Wales, Australia. 3. Northern Clinical School, University of Sydney, Sydney, New South Wales, Australia; Upper GI Surgical Unit, Royal North Shore Hospital and North Shore Private Hospital, Sydney, New South Wales, Australia. 4. Northern Clinical School, University of Sydney, Sydney, New South Wales, Australia; Upper GI Surgical Unit, Royal North Shore Hospital and North Shore Private Hospital, Sydney, New South Wales, Australia. Electronic address: tom.hugh@sydney.edu.au.
Abstract
BACKGROUND: Colorectal cancer (CRC) accounts for 9.7% of all cancers with 1.4 million new cases diagnosed each year. 19-31% of CRC patients develop colorectal liver metastases (CRLM), and 23-38% develop extra-hepatic disease (EHD). The aim of this systematic review was to determine overall survival (OS) in patients resected for CRLM and known EHD. METHODS: A systematic review was undertaken to identify studies reporting OS after resection for CRLM in the presence of EHD. Proportional meta-analyses and relative risk of death before five years were assessed between patient groups. RESULTS: A total of 15,144 patients with CRLM (2308 with EHD) from 52 studies were included. Three and 5-year OS were 58% and 26% for lung, 37% and 17% for peritoneum, and 35% and 15% for lymph nodes, respectively. The combined relative risk of death by five years was 1.49 (95% CI = 1.34-1.66) for lung, 1.59 (95% CI = 1.16-2.17) for peritoneal and 1.70 (95% CI = 1.57-1.84) for lymph node EHD, in favour of resection in the absence of EHD. CONCLUSION: This review supports attempts at R0 resection in selected patients and rejects the notion that EHD is an absolute contraindication to resection.
BACKGROUND:Colorectal cancer (CRC) accounts for 9.7% of all cancers with 1.4 million new cases diagnosed each year. 19-31% of CRCpatients develop colorectal liver metastases (CRLM), and 23-38% develop extra-hepatic disease (EHD). The aim of this systematic review was to determine overall survival (OS) in patients resected for CRLM and known EHD. METHODS: A systematic review was undertaken to identify studies reporting OS after resection for CRLM in the presence of EHD. Proportional meta-analyses and relative risk of death before five years were assessed between patient groups. RESULTS: A total of 15,144 patients with CRLM (2308 with EHD) from 52 studies were included. Three and 5-year OS were 58% and 26% for lung, 37% and 17% for peritoneum, and 35% and 15% for lymph nodes, respectively. The combined relative risk of death by five years was 1.49 (95% CI = 1.34-1.66) for lung, 1.59 (95% CI = 1.16-2.17) for peritoneal and 1.70 (95% CI = 1.57-1.84) for lymph node EHD, in favour of resection in the absence of EHD. CONCLUSION: This review supports attempts at R0 resection in selected patients and rejects the notion that EHD is an absolute contraindication to resection.
Authors: Dominique Elias; Gabriel Liberale; Déwi Vernerey; Marc Pocard; Michel Ducreux; Valérie Boige; David Malka; Jean-Pierre Pignon; Philippe Lasser Journal: Ann Surg Oncol Date: 2005-09-26 Impact factor: 5.344
Authors: Michael G House; Hiromichi Ito; Mithat Gönen; Yuman Fong; Peter J Allen; Ronald P DeMatteo; Murray F Brennan; Leslie H Blumgart; William R Jarnagin; Michael I D'Angelica Journal: J Am Coll Surg Date: 2010-05 Impact factor: 6.113
Authors: Rui Niu; Tristan D Yan; Jacqui C Zhu; Deborah Black; Francis Chu; David L Morris Journal: Ann Surg Oncol Date: 2007-05-02 Impact factor: 5.344
Authors: René Adam; Robbert J de Haas; Dennis A Wicherts; Thomas A Aloia; Valérie Delvart; Daniel Azoulay; Henri Bismuth; Denis Castaing Journal: J Clin Oncol Date: 2008-08-01 Impact factor: 44.544
Authors: K S Hughes; R Simon; S Songhorabodi; M A Adson; D M Ilstrup; J G Fortner; B J Maclean; J H Foster; J M Daly; D Fitzherbert Journal: Surgery Date: 1986-08 Impact factor: 3.982
Authors: Ajith K Siriwardena; James M Mason; Saifee Mullamitha; Helen C Hancock; Santhalingam Jegatheeswaran Journal: Nat Rev Clin Oncol Date: 2014-06-03 Impact factor: 66.675
Authors: Jacques Ferlay; Isabelle Soerjomataram; Rajesh Dikshit; Sultan Eser; Colin Mathers; Marise Rebelo; Donald Maxwell Parkin; David Forman; Freddie Bray Journal: Int J Cancer Date: 2014-10-09 Impact factor: 7.396
Authors: Alan I Valderrama-Treviño; Baltazar Barrera-Mera; Jesús C Ceballos-Villalva; Eduardo E Montalvo-Javé Journal: Euroasian J Hepatogastroenterol Date: 2017-09-29
Authors: Elske C Gootjes; Eric P van der Stok; Cornelis Verhoef; Henk M W Verheul; Tineke E Buffart; Lotte Bakkerus; Mariette Labots; Barbara M Zonderhuis; Jurriaan B Tuynman; Martijn R Meijerink; Peter M van de Ven; Cornelis J A Haasbeek; Albert J Ten Tije; Jan-Willem B de Groot; Mathijs P Hendriks; Esther van Meerten; Joost J M E Nuyttens; Dirk J Grunhagen Journal: Oncologist Date: 2020-06-16
Authors: Pieter M H Nierop; Boris Galjart; Diederik J Höppener; Eric P van der Stok; Robert R J Coebergh van den Braak; Peter B Vermeulen; Dirk J Grünhagen; Cornelis Verhoef Journal: Clin Exp Metastasis Date: 2019-03-06 Impact factor: 5.150